+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Kinase"

Receptor Type Tyrosine Protein Kinase FLT3 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Receptor Type Tyrosine Protein Kinase FLT3 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 113 Pages
  • Global
From
Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 248 Pages
  • Global
From
Protein Kinase C Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Protein Kinase C Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 83 Pages
  • Global
From
Receptor Interacting Serine-Threonine Protein Kinase 1 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Receptor Interacting Serine-Threonine Protein Kinase 1 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 51 Pages
  • Global
From
p38 MAP Kinase Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

p38 MAP Kinase Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 63 Pages
  • Global
From
Bcr-Abl Tyrosine Kinase Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Bcr-Abl Tyrosine Kinase Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 61 Pages
  • Global
From
Phosphatidylinositol 3 Kinase Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Phosphatidylinositol 3 Kinase Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 170 Pages
  • Global
From
Vascular Endothelial Growth Factor Receptor 1 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Vascular Endothelial Growth Factor Receptor 1 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 77 Pages
  • Global
From
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 79 Pages
  • Global
From
Vascular Endothelial Growth Factor Receptor 2 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Vascular Endothelial Growth Factor Receptor 2 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 138 Pages
  • Global
From
Receptor Tyrosine Protein Kinase ERBB 2 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Receptor Tyrosine Protein Kinase ERBB 2 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 173 Pages
  • Global
From
ALK Tyrosine Kinase Receptor Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

ALK Tyrosine Kinase Receptor Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 67 Pages
  • Global
From
Protein Kinase B Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Protein Kinase B Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 71 Pages
  • Global
From
Serine-Threonine Protein Kinase B Raf Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Serine-Threonine Protein Kinase B Raf Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 76 Pages
  • Global
From
Cells Expressing Inactive Tyrosine Protein Kinase Transmembrane Receptor ROR1 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Cells Expressing Inactive Tyrosine Protein Kinase Transmembrane Receptor ROR1 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 54 Pages
  • Global
From
Cells Expressing Receptor Tyrosine Protein Kinase ERBB 3 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Cells Expressing Receptor Tyrosine Protein Kinase ERBB 3 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 49 Pages
  • Global
From
Cells Expressing Ephrin Type A Receptor 2 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Cells Expressing Ephrin Type A Receptor 2 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 45 Pages
  • Global
From
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • April 2022
  • 71 Pages
  • Global
From
3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • April 2022
  • 45 Pages
  • Global
From
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • April 2022
  • 100 Pages
  • Global
From
Loading Indicator

The Kinase market is a subset of the Drug Discovery market, focusing on the development of drugs that target kinases, a type of enzyme that plays a role in many cellular processes. Kinase inhibitors are used to treat a variety of diseases, including cancer, diabetes, and neurological disorders. Kinase inhibitors are typically small molecules that bind to the active site of the kinase, blocking its activity. Kinase inhibitors are developed through a combination of in vitro and in vivo assays, as well as computational modeling. Companies in the Kinase market are focused on developing novel inhibitors that can be used to treat a variety of diseases. These companies include AbbVie, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more